| Today’s Big NewsJan 10, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now.
|
|
| By Annalee Armstrong Eli Lilly CEO David Ricks, speaking to the slow and steady progress that brought tirzepitide to the world, says the Indianapolis pharma is now ready to open up the chocolate factory. |
|
|
|
By Max Bayer CRISPR Therapeutics board member Simeon George said it's "still early days" for the company's pursuit of new partners, saying more work has to be done on coming to potential deal terms. |
By Annalee Armstrong,Gabrielle Masson,James Waldron,Max Bayer,Ben Adams We're off for another day of the J.P. Morgan Healthcare Conference 2024. The flood of licensing deals and M&A may have slowed, but there's still plenty of action to come as companies make pitches to their peers, investors and industry watchers. |
By Nick Paul Taylor Coherus BioSciences wants to get off the TIGIT rollercoaster. Less than two years after paying $35 million to exercise its option, the biotech has told Junshi Biosciences it is dropping the TIGIT asset CHS-006 from the collaboration. |
By James Waldron A total of 45 positions will be impacted, with the changes likely to be completed by the end of the quarter. |
By Nick Paul Taylor Alcon’s $770 million takeover of Aerie Pharmaceuticals has delivered an early win. The lead candidate in the acquired pipeline met the primary endpoint in a pair of phase 3 dry eye trials, positioning Alcon to file for FDA approval in the middle of the year. |
By James Waldron Aclaris Therapeutics has touted the latest phase 2 results for its “soft” JAK 1/3 inhibitor as a win for the beleaguered biotech, but investors appeared to have been spooked by the wider set out mixed data. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron,Ben Adams Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2024 in San Francisco. Yesterday Merger Monday lived up to its name with deals for Novartis, J&J and Merck, and today, we’re also starting the day with an early deal. Check out all the updates from JPM below. |
By Joseph Keenan Labcorp, which spun off its CRO arm last year, inked a collaboration deal with trial software firm Hawthorne Effect to speed up decentralized clinical trials and increase patient diversity. |
By Conor Hale Presenting at the J.P. Morgan Healthcare Conference in San Francisco, the company reported about $1.12 billion in revenue from last year’s fourth quarter, representing a gain of 3% over the same period the year before. |
By Zoey Becker,Fraiser Kansteiner,Kevin Dunleavy,Angus Liu,Eric Sagonowsky On Wednesday at the the J.P. Morgan Healthcare Conference, attendees will get a chance to hear from AbbVie, Amarin and several other pharmaceutical companies. |
By Nick Paul Taylor AcelRx Pharmaceuticals wants to put a tough few years behind it. After failing to crack the pain market, the biotech has shifted its focus to a pipeline led by a blood thinner and adopted a new name, Talphera, to reflect the revised strategy. |
By Anastassia Gliadkovskaya While most behavioral and surgical treatment studies reveal disparities in weight loss and clinical outcomes, pharmacological studies reveal minimal to no evidence of disparities and favorable outcomes for minorities. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
